NCT02897115View on ClinicalTrials.gov

A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

PHASE4TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 12, 2016

Primary Completion Date

December 21, 2017

Study Completion Date

December 21, 2017

Conditions
Axial Spondyloarthritis
Interventions
BIOLOGICAL

Adalimumab

Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.

OTHER

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

ASAS recommended NSAID doses to treat axial spondyloarthritis.

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
collaborator

IST GmbH, Germany

INDUSTRY

collaborator

Hannover Medical School

OTHER

collaborator

Improvement by Movement GmbH, Germany

UNKNOWN

lead

AbbVie

INDUSTRY